Biodesix, Inc. (BDSX) 주식 분석

회사 개요

Biodesix, Inc. operates within the healthcare sector, specifically focusing on the diagnostics and research industry by providing diagnostic solutions that assess lung health through blood-based testing. The company's primary offering includes the Nodify XL2 and Nodify CDT tests, which function as Nodify Lung Nodule Risk Assessment tools to evaluate the risk of lung cancer and assist clinicians in identifying appropriate treatment pathways. With a market capitalization of $131.31M and an annual revenue of $88.50M over the trailing twelve months, the firm employs a workforce of 334 individuals to deliver these specialized diagnostic services. These financial figures indicate that Biodesix positions itself as a mid-cap entity with significant revenue generation capabilities, yet the valuation metrics suggest the market prices the stock with a premium relative to its book value while acknowledging the company's current profitability challenges in its growth phase.

재무 건전성

The company reported revenue of $88.50M for the trailing twelve months, but this revenue figure masks a net income loss of $35,265,000 and an EBITDA of $-22,096,000, revealing a substantial gap where operating expenses significantly outpace earnings before interest, taxes, depreciation, and amortization. This negative EBITDA and net income structure implies that the company is currently prioritizing research and development or market expansion over immediate profit generation, resulting in a negative free cash flow of $-11,825,250 which limits financial flexibility for external expansion without capital raises. The gross margin stands at 81.1%, indicating highly efficient cost of goods sold relative to revenue, while the operating margin of -6.8% and profit margin of -39.8% highlight the heavy burden of operating expenses and the resulting bottom-line erosion. On the balance sheet, the company holds $18.99M in cash against $75.03M in debt, a position that appears leveraged given the lack of reported equity in standard debt-to-equity calculations, although the current ratio of 1.86 suggests adequate short-term liquidity to cover immediate obligations. The return on equity is -383.1% and the return on assets is -18.8%, metrics that collectively reveal that management has not yet generated positive returns on capital deployed, reflecting the high-risk nature of the business model in its current lifecycle stage.

밸류에이션 평가

Valuation metrics for Biodesix show a trailing P/E ratio that is technically N/A due to negative earnings, while the forward P/E is listed at -60.55, implying that future earnings expectations remain negative and do not yet support a traditional earnings-based multiple. The price-to-book ratio is -44.55, indicating that the market price is priced significantly below the company's book value, a scenario often seen in growth-stage biotech firms where intangible assets and future potential outweigh current accounting equity. Alternative valuation metrics include a price-to-sales ratio of 1.48 and an EV/EBITDA of -8.48, which suggest the market is willing to pay a moderate premium based on sales volume despite the lack of profitability. The stock trades within a 52-week range bounded by a high of $20.21 and a low of $3.44, placing the current share price in a volatile zone where it has experienced substantial price discovery since the recent lows. The beta of 0.57 indicates that the stock exhibits lower volatility relative to the broader market, suggesting that price movements are less sensitive to general market swings compared to large-cap equities.

Growth & Income

Revenue growth year-over-year stands at 40.8%, demonstrating a robust expansion in sales volume, whereas earnings growth is N/A due to the absence of net income, meaning revenue expansion is not yet translating into proportional profitability improvements. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which indicates a strategy of retaining all earnings to fund operations and growth initiatives rather than distributing cash to shareholders. This reinvestment approach is typical for diagnostic companies in the development phase, where capital is required to sustain the high gross margins of 81.1% while covering the significant operating losses that result in a -39.8% profit margin. Overall, the growth and income profile characterizes Biodesix as a high-revenue-growth company with zero current income distribution, relying entirely on its substantial cash reserves and future potential to navigate its path toward profitability.